

Bertrand Audoin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7114260/publications.pdf>

Version: 2024-02-01

78
papers

4,332
citations

101496

36
h-index

114418

63
g-index

81
all docs

81
docs citations

81
times ranked

4047
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. <i>Neurology</i> , 2018, 90, e1858-e1869.	1.5	401
2	Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of multiple sclerosis. <i>Human Brain Mapping</i> , 2003, 20, 51-58.	1.9	237
3	Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 124-127.	1.4	223
4	Magnetic resonance study of the influence of tissue damage and cortical reorganization on PASAT performance at the earliest stage of multiple sclerosis. <i>Human Brain Mapping</i> , 2005, 24, 216-228.	1.9	167
5	Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. <i>NeuroImage</i> , 2019, 184, 901-915.	2.1	163
6	Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 690-695.	0.9	140
7	Assessing brain connectivity at rest is clinically relevant in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1251-1258.	1.4	133
8	Modulation of effective connectivity inside the working memory network in patients at the earliest stage of multiple sclerosis. <i>NeuroImage</i> , 2005, 24, 533-538.	2.1	128
9	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. <i>Annals of Neurology</i> , 2021, 89, 30-41.	2.8	123
10	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	3.1	115
11	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	0.9	110
12	Localization of grey matter atrophy in early RRMS. <i>Journal of Neurology</i> , 2006, 253, 1495-1501.	1.8	102
13	Altered Functional Connectivity Related to White Matter Changes inside the Working Memory Network at the Very Early Stage of MS. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1245-1253.	2.4	101
14	Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. <i>Annals of Neurology</i> , 2020, 87, 256-266.	2.8	100
15	Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. <i>NeuroImage</i> , 2007, 37, 253-261.	2.1	99
16	Structure of WM bundles constituting the working memory system in early multiple sclerosis: A quantitative DTI tractography study. <i>NeuroImage</i> , 2007, 36, 1324-1330.	2.1	98
17	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1377-1384.	1.4	89
18	Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. <i>Brain</i> , 2006, 129, 1031-1039.	3.7	88

#	ARTICLE	IF	CITATIONS
19	Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. <i>Journal of Neurology</i> , 2015, 262, 2329-2335.	1.8	86
20	Voxel-based analysis of MTR images: A method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2004, 20, 765-771.	1.9	85
21	Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. <i>Brain</i> , 2019, 142, 633-646.	3.7	75
22	Evaluation of efficacy and tolerability of first-line therapies in NMOSD. <i>Neurology</i> , 2020, 94, e1645-e1656.	1.5	66
23	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	64
24	Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. <i>Journal of the Neurological Sciences</i> , 2017, 373, 335-338.	0.3	58
25	MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 554-565.	1.4	56
26	Efficacy of rituximab in refractory neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2016, 22, 955-959.	1.4	55
27	Depletion of brain functional connectivity enhancement leads to disability progression in multiple sclerosis: A longitudinal resting-state fMRI study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1695-1708.	1.4	54
28	Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis - a two-year longitudinal MRI/MRSI study of corpus callosum. <i>Multiple Sclerosis Journal</i> , 2007, 13, 41-51.	1.4	50
29	Structural and functional surrogates of cognitive impairment at the very early stage of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2006, 245, 161-167.	0.3	49
30	Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	49
31	Efficiency of cognitive control recruitment in the very early stage of multiple sclerosis: a one-year fMRI follow-up study. <i>Multiple Sclerosis Journal</i> , 2008, 14, 786-792.	1.4	48
32	Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. <i>Revue Neurologique</i> , 2018, 174, 255-264.	0.6	47
33	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. <i>Journal of Neurology</i> , 2019, 266, 806-815.	1.8	47
34	Mind the gap: from neurons to networks to outcomes in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2021, 17, 173-184.	4.9	46
35	Prevalence of Grey Matter Pathology in Early Multiple Sclerosis Assessed by Magnetization Transfer Ratio Imaging. <i>PLoS ONE</i> , 2011, 6, e24969.	1.1	45
36	Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 483-489.	1.4	44

#	ARTICLE	IF	CITATIONS
37	Increased total sodium concentration in gray matter better explains cognition than atrophy in MS. <i>Neurology</i> , 2017, 88, 289-295.	1.5	40
38	White matter damage impairs access to consciousness in multiple sclerosis. <i>NeuroImage</i> , 2009, 44, 590-599.	2.1	37
39	Longitudinal fMRI studies: Exploring brain plasticity and repair in MS. <i>Multiple Sclerosis Journal</i> , 2016, 22, 269-278.	1.4	37
40	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 936-944.	1.4	37
41	Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	36
42	Hypoperfusion of the thalamus is associated with disability in relapsing remitting multiple sclerosis. <i>Journal of Neuroradiology</i> , 2017, 44, 158-164.	0.6	34
43	Metabolic voxel-based analysis of the complete human brain using fast 3D-MRSI: Proof of concept in multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 411-419.	1.9	31
44	Efficacy of rituximab in refractory RRMS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 828-836.	1.4	28
45	Intact subliminal processing and delayed conscious access in multiple sclerosis. <i>Neuropsychologia</i> , 2007, 45, 2683-2691.	0.7	26
46	The long-term outcome of MOGAD: An observational national cohort study of 61 patients. <i>European Journal of Neurology</i> , 2021, 28, 1659-1664.	1.7	26
47	Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	26
48	Brain MRI features and scoring of leukodystrophy in adult-onset Krabbe disease. <i>Neurology</i> , 2019, 93, e647-e652.	1.5	25
49	Effects of cognitive impairment on prosodic parameters of speech production planning in multiple sclerosis. <i>Journal of Neuropsychology</i> , 2019, 13, 22-45.	0.6	24
50	Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat. <i>Journal of Neurology</i> , 2016, 263, 927-936.	1.8	20
51	A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2025-2037.	1.7	20
52	In vivo quantification of brain injury in adult Niemann-Pick Disease Type C. <i>Molecular Genetics and Metabolism</i> , 2011, 103, 138-141.	0.5	18
53	Occurrence of neuronal dysfunction during the first 5 years of multiple sclerosis is associated with cognitive deterioration. <i>Journal of Neurology</i> , 2011, 258, 811-819.	1.8	17
54	Longitudinal study of functional brain network reorganization in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2020, 26, 188-200.	1.4	17

#	ARTICLE	IF	CITATIONS
55	Sensitivity of the Inhomogeneous Magnetization Transfer Imaging Technique to Spinal Cord Damage in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020, 41, 929-937.	1.2	16
56	MRI characteristics of MOG-Ab associated disease in adults: An update. <i>Revue Neurologique</i> , 2021, 177, 39-50.	0.6	15
57	New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: A ten-year longitudinal study. <i>PLoS ONE</i> , 2017, 12, e0184650.	1.1	15
58	Individual voxel-based analysis of brain magnetization transfer maps shows great variability of gray matter injury in the first stage of multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 32, 424-428.	1.9	14
59	Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain ²³ Na-MRI and fast ¹ H-MRSI study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 39-47.	1.4	14
60	Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 712-718.	1.4	13
61	Motor cortical reorganization is present after a single attack of multiple sclerosis devoid of cortico-spinal dysfunction. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2011, 24, 77-84.	1.1	11
62	Voxelwise analysis of conventional magnetic resonance imaging to predict future disability in early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1585-1591.	1.4	11
63	Brain functional plasticity at rest and during action in multiple sclerosis patients. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1438-1443.	0.8	10
64	Aerobic Exercise Induces Functional and Structural Reorganization of CNS Networks in Multiple Sclerosis: A Randomized Controlled Trial. <i>Frontiers in Human Neuroscience</i> , 2020, 14, 255.	1.0	10
65	Comparison of rituximab originator (MabThera [®]) to biosimilar (Truxima [®]) in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 585-592.	1.4	10
66	Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease. <i>Multiple Sclerosis Journal</i> , 2021, 27, 320-323.	1.4	8
67	TNF- α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 890-896.	0.9	8
68	Improved Cervical Cord Lesion Detection with 3D-MP2RAGE Sequence in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020, 41, 1131-1134.	1.2	7
69	How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update. <i>Revue Neurologique</i> , 2018, 174, 429-440.	0.6	6
70	Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110621.	0.5	6
71	Pure Relapsing Short Myelitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	5
72	Advanced magnetic resonance imaging techniques to better understand multiple sclerosis. <i>Biophysical Reviews</i> , 2010, 2, 83-90.	1.5	3

#	ARTICLE	IF	CITATIONS
73	Grey-matter sodium concentration as an individual marker of multiple sclerosis severity. Multiple Sclerosis Journal, 2022, 28, 1903-1912.	1.4	2
74	Delayed access to conscious processing in multiple sclerosis: Reduced cortical activation and impaired structural connectivity. Human Brain Mapping, 2021, 42, 3379-3395.	1.9	1
75	Suivi IRM des patients SEPÂ: pourquoiÂ?. Pratique Neurologique - FMC, 2016, 7, 149-152.	0.1	0
76	Processus conscients et non conscients. , 2010, , 123-127.		0
77	MÃ©thodes de RMN avancÃ©es et explorations intÃ©grÃ©es. , 2010, , 165-175.		0
78	Author Response: Evaluation of Efficacy and Tolerability of First-Line Therapies in NMOSD. Neurology, 2021, 96, 295-296.	1.5	0